<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01159431</url>
  </required_header>
  <id_info>
    <org_study_id>TNS-TDP-01</org_study_id>
    <nct_id>NCT01159431</nct_id>
  </id_info>
  <brief_title>External Trigeminal Nerve Stimulation for Epilepsy</brief_title>
  <official_title>Randomized Double Blind Study of External Trigeminal Nerve Stimulation for Intractable Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olive View-UCLA Education &amp; Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Epilepsy Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Olive View-UCLA Education &amp; Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates a new therapy for epilepsy called Trigeminal Nerve Stimulation (TNS).
      TNS involves external electrical stimulation of sensory nerve located above the eyes and over
      the forehead. The purpose of this study is to determine if TNS is safe and effective using a
      rigorous randomized active-control clinical trial design in 50 people with epilepsy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Poorly controlled epilepsy is a disabling condition, affecting over one million Americans.
      Neurostimulation is a promising alternative for patients who have failed medical therapy, and
      who are not resective surgical candidates.

      Trigeminal Nerve Stimulation (TNS) is a novel form of neurostimulation, and has a strong
      antiepileptic effect in an animal model of seizures. Preliminary data in humans indicates TNS
      is well tolerated and may be effective in people with intractable epilepsy.

      TNS is an alternative mode of neurostimulation, because the Trigeminal Nerve can be
      stimulated in minimally-invasive fashion.

      This is a randomized double blind study of Trigeminal Nerve Stimulation, which compares high
      stimulation to an active control. Subjects with poorly controlled partial onset seizures who
      meet all inclusion and exclusion criteria, enter a 6-week baseline period, and then are
      randomized in double-blind fashion to high or low intensity stimulation for 18 weeks. 50
      subjects are to be enrolled at two sites.

      Study outcomes are the following:

        1. Percent change in seizure frequency during the treatment period compared with the
           baseline (pre-treatment) period.

        2. Time to the 4th seizure

      The primary comparisons will be between and within groups.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>50% Responder Rate</measure>
    <time_frame>Treatment period, 18 weeks (end of double blind period) compared with first 6 weeks</time_frame>
    <description>Change in responder rate, at end of study (18 weeks)
Absolute percent of subjects with 50% reduction in seizures, 18 weeks compared with 6 weeks Note, the number is not a mean or median, but a fixed percentage.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to the 4th Seizure</measure>
    <time_frame>treatment period (18-weeks)</time_frame>
    <description>Number of Days to the 4th seizure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Seizure Frequency</measure>
    <time_frame>18 weeks</time_frame>
    <description>Percent change in seizure frequency from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response Ratio: Mean Percent Change in Seizures</measure>
    <time_frame>18 weeks</time_frame>
    <description>Response Ratio: Mean Percent Change in seizures over the treatment period, where [T-B] / [T+B] x 100%, where T = seizure frequency during the treatment period, and B = seizure frequency during the baseline period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mood</measure>
    <time_frame>18-weeks</time_frame>
    <description>Mean change in score on the Beck Depression Inventory. The Beck Inventory is a patient reported mood scale. The minimum score is 0, and the maximum score is 63. Scores of less than 10 are considered in the normal range. Scores above 10 are consistent with depression. Higher scores indicate higher degrees of depression, with scores of &gt; 25 consistent with severe depression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Epilepsy</condition>
  <condition>Seizure Disorders</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Trigeminal Nerve Stimulation</intervention_name>
    <description>External stimulation of the supraorbital branch of the Trigeminal Nerve using a digital TENs unit</description>
    <arm_group_label>Active</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18 - 70;

          -  No serious or progressive medical illness;

          -  A history of intractable partial seizures;

          -  At least two complex partial or tonic clonic generalized seizures per month in the
             last two consecutive months;

          -  MRI or EEG consistent with localization-related or partial epilepsy;

          -  Exposure to at least two antiepileptic drugs at adequate doses;

          -  Concurrent use of at least one antiepileptic drug at adequate doses;

          -  No change in antiepileptic dose for at least 30 days before study enrollment

        Exclusion Criteria:

          -  History of non-epileptic seizures;

          -  Inability to maintain accurate seizure calendars (self or caregiver);

          -  Frequent use of benzodiazepines for clusters defined as greater than four times a
             month;

          -  History of facial pain or trigeminal neuralgia;

          -  Concurrent vagus nerve stimulation;

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher M DeGiorgio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA Department of Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christi Heck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>USC Department of Neurology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olive View/UCLA Medical Center</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>DeGiorgio CM, Murray D, Markovic D, Whitehurst T. Trigeminal nerve stimulation for epilepsy: long-term feasibility and efficacy. Neurology. 2009 Mar 10;72(10):936-8. doi: 10.1212/01.wnl.0000344181.97126.b4.</citation>
    <PMID>19273830</PMID>
  </reference>
  <results_reference>
    <citation>DeGiorgio CM, Soss J, Cook IA, Markovic D, Gornbein J, Murray D, Oviedo S, Gordon S, Corralle-Leyva G, Kealey CP, Heck CN. Randomized controlled trial of trigeminal nerve stimulation for drug-resistant epilepsy. Neurology. 2013 Feb 26;80(9):786-91. doi: 10.1212/WNL.0b013e318285c11a. Epub 2013 Jan 30.</citation>
    <PMID>23365066</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2010</study_first_submitted>
  <study_first_submitted_qc>July 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2010</study_first_posted>
  <results_first_submitted>February 1, 2013</results_first_submitted>
  <results_first_submitted_qc>May 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2013</results_first_posted>
  <last_update_submitted>May 6, 2013</last_update_submitted>
  <last_update_submitted_qc>May 6, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Olive View-UCLA Education &amp; Research Institute</investigator_affiliation>
    <investigator_full_name>Christopher DeGiorgio</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>partial seizures</keyword>
  <keyword>poorly controlled epilepsy</keyword>
  <keyword>intractable epilepsy</keyword>
  <keyword>treatment resistant epilepsy</keyword>
  <keyword>Trigeminal Nerve</keyword>
  <keyword>Trigeminal Nerve Stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Drug Resistant Epilepsy</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited beginning at Olive View/UCLA and Keck-USC between 3/2008 and 10/2010</recruitment_details>
      <pre_assignment_details>6-week pretreatment baseline</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active</title>
          <description>Trigeminal Nerve Stimulation-High Settings</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>Trigeminal Nerve Stimulation-Low Settings</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active</title>
          <description>Trigeminal Nerve Stimulation-High Settings</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>Trigeminal Nerve Stimulation-Low Settings</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.1" spread="10.57"/>
                    <measurement group_id="B2" value="34.2" spread="10.81"/>
                    <measurement group_id="B3" value="33.44" spread="10.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>50% Responder Rate</title>
        <description>Change in responder rate, at end of study (18 weeks)
Absolute percent of subjects with 50% reduction in seizures, 18 weeks compared with 6 weeks Note, the number is not a mean or median, but a fixed percentage.</description>
        <time_frame>Treatment period, 18 weeks (end of double blind period) compared with first 6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Trigeminal Nerve Stimulation-High Settings</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Trigeminal Nerve Stimulation-Low Settings</description>
          </group>
        </group_list>
        <measure>
          <title>50% Responder Rate</title>
          <description>Change in responder rate, at end of study (18 weeks)
Absolute percent of subjects with 50% reduction in seizures, 18 weeks compared with 6 weeks Note, the number is not a mean or median, but a fixed percentage.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5"/>
                    <measurement group_id="O2" value="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to the 4th Seizure</title>
        <description>Number of Days to the 4th seizure</description>
        <time_frame>treatment period (18-weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Control Group-Baseline</title>
            <description>Baseline</description>
          </group>
          <group group_id="O2">
            <title>Control Group-Double Blind Period</title>
            <description>Sham Treatment</description>
          </group>
          <group group_id="O3">
            <title>Treatment Group-Baseline</title>
          </group>
          <group group_id="O4">
            <title>Treatment Group-Double Blind Period</title>
          </group>
        </group_list>
        <measure>
          <title>Time to the 4th Seizure</title>
          <description>Number of Days to the 4th seizure</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23" spread="19"/>
                    <measurement group_id="O2" value="18" spread="31"/>
                    <measurement group_id="O3" value="12.5" spread="18"/>
                    <measurement group_id="O4" value="15" spread="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Ratio: Mean Percent Change in Seizures</title>
        <description>Response Ratio: Mean Percent Change in seizures over the treatment period, where [T-B] / [T+B] x 100%, where T = seizure frequency during the treatment period, and B = seizure frequency during the baseline period.</description>
        <time_frame>18 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
          </group>
          <group group_id="O2">
            <title>Control</title>
          </group>
        </group_list>
        <measure>
          <title>Response Ratio: Mean Percent Change in Seizures</title>
          <description>Response Ratio: Mean Percent Change in seizures over the treatment period, where [T-B] / [T+B] x 100%, where T = seizure frequency during the treatment period, and B = seizure frequency during the baseline period.</description>
          <units>percentage change of RRATIO</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.9" spread="6.7"/>
                    <measurement group_id="O2" value="-9.0" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in Seizure Frequency</title>
        <description>Percent change in seizure frequency from baseline</description>
        <time_frame>18 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Trigeminal Nerve Stimulation-High Settings</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Trigeminal Nerve Stimulation-Low Settings</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Seizure Frequency</title>
          <description>Percent change in seizure frequency from baseline</description>
          <units>percentage change in seizures per month</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.1" spread="15.4"/>
                    <measurement group_id="O2" value="-10.5" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mood</title>
        <description>Mean change in score on the Beck Depression Inventory. The Beck Inventory is a patient reported mood scale. The minimum score is 0, and the maximum score is 63. Scores of less than 10 are considered in the normal range. Scores above 10 are consistent with depression. Higher scores indicate higher degrees of depression, with scores of &gt; 25 consistent with severe depression.</description>
        <time_frame>18-weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active</title>
            <description>Trigeminal Nerve Stimulation-High Settings</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Trigeminal Nerve Stimulation-Low Settings</description>
          </group>
        </group_list>
        <measure>
          <title>Mood</title>
          <description>Mean change in score on the Beck Depression Inventory. The Beck Inventory is a patient reported mood scale. The minimum score is 0, and the maximum score is 63. Scores of less than 10 are considered in the normal range. Scores above 10 are consistent with depression. Higher scores indicate higher degrees of depression, with scores of &gt; 25 consistent with severe depression.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.13" spread="1.35"/>
                    <measurement group_id="O2" value="-3.95" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18-weeks</time_frame>
      <desc>anxiety</desc>
      <group_list>
        <group group_id="E1">
          <title>Active</title>
          <description>Trigeminal Nerve Stimulation-High Settings</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Trigeminal Nerve Stimulation-Low Settings</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure cluster</sub_title>
                <description>Seizure cluster requiring visit to the ER, not device related.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>skin irritation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to sample size and high variability in seizure frequency, median change did not achieve significance. To constrain variability, the RRATIO was used to assess seizure frequency. The RRATIO demonstrated within groups differences, p=0.04 ANOVA.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Christopher DeGiorgio</name_or_title>
      <organization>UCLA</organization>
      <phone>310-206-3753</phone>
      <email>cmd@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

